Multiple Myeloma
Feature
Outpatient CAR T: Safe, Effective, Accessible
'The future of CAR T-cell therapy lies in balancing safety with accessibility,' says expert.
Conference Coverage
Multi-Refractory MM: After Immunotherapy, What?
Experts outlined viable remaining options for treating multi-refractory myeloma, following immunotherapy.
Feature
For Radiation ‘Downwinders,’ Cancer Compensation Is On Hold
A federal program to compensate patients whose exposure to radiation caused cancer has expired, but screenings and efforts to revive and expand...
Conference Coverage
Myeloma: Isa-KRd Induction Shows High MRD Responses
Interim analysis of first MIDAS trial findings shows “highest rate of response and MRD negativity to date.”
Conference Coverage
Isatuximab Quadruplet Approval Could Change the Landscape for Treating Myeloma
Findings of phase 3 IMROZ trial demonstrated the efficacy of Isa-VRd, a four-drug combo, in treating patients newly diagnosed with myeloma.
Sponsored Supplement
Multiple Myeloma: A New Treatment Option for Newly Diagnosed, Transplant-Ineligible Patients
Conference Coverage
MM: First CAR T-Cell Therapy to Exhibit OS Benefit
CARTITUDE-4 study update indicated that CAR T-cell therapy improves overall survival in relapsed/refractory multiple myeloma.
Conference Coverage
Daratumumab Quadruplet Supported Transplant-Ineligible MM
A phase-3 study showed that adding daratumumab to VRd yields a primary endpoint of MRD negativity in patients newly diagnosed with myeloma.
Conference Coverage
Myeloma: Daratumumab Plus Lenalidomide Improves MRD Outcomes
New research shows that adding daratumumab to maintenance therapy improves MRD and PFS outcomes in multiple myeloma.
From the Journals
Does Medicare Advantage Offer Higher-Value Chemotherapy?
Researchers conducted a cohort study to look at Medicare Advantage enrollment and treatment patterns for patients with cancer receiving...
Feature
AACR Cancer Progress Report: Big Strides and Big Gaps
The report focused on strides made in cancer care, prevention, and early detection and highlighted areas where more research and attention are...
News
Isatuximab Approved First-Line for Transplant-Ineligible MM
FDA greenlighted expansion of a biologic to treat patients newly diagnosed with myeloma for whom transplants are not an option.